BAMF
REGN icon

BI Asset Management Fondsmaeglerselskab’s Regeneron Pharmaceuticals REGN Stock Holding History

BI Asset Management Fondsmaeglerselskab’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.2M Buy
5,132
+1,893
+58% +$1.29M 0.03% 343
2026
Q1 		$2.5M Sell
3,239
-2,968
-48% -$2.27M 0.03% 346
2025
Q4 		$4.79M Buy
6,207
+1,974
+47% +$1.34M 0.04% 276
2025
Q3 		$2.38M Sell
4,233
-751
-15% -$425K 0.02% 383
2025
Q2 		$2.62M Buy
4,984
+476
+11% +$266K 0.03% 324
2025
Q1 		$2.86M Sell
4,508
-111
-2% -$76.3K 0.03% 300
2024
Q4 		$3.29M Buy
4,619
+1,297
+39% +$1.09M 0.03% 277
2024
Q3 		$3.49M Buy
3,322
+120
+4% +$134K 0.06% 223
2024
Q2 		$3.37M Sell
3,202
-1,577
-33% -$1.53M 0.06% 234
2024
Q1 		$4.6M Buy
4,779
+285
+6% +$271K 0.09% 179
2023
Q4 		$3.95M Sell
4,494
-4,978
-53% -$4.1M 0.08% 187
2023
Q3 		$7.79M Sell
9,472
-10,583
-53% -$8.32M 0.18% 112
2023
Q2 		$14.4M Buy
20,055
+194
+1% +$150K 0.34% 73
2023
Q1 		$16.3M Sell
19,861
-4,727
-19% -$3.57M 0.43% 62
2022
Q4 		$17.7M Buy
24,588
+8,607
+54% +$6.35M 0.47% 61
2022
Q3 		$11M Sell
15,981
-15,689
-50% -$9.87M 0.56% 51
2022
Q2 		$18.7M Buy
31,670
+503
+2% +$327K 0.8% 38
2022
Q1 		$21.8M Sell
31,167
-6,584
-17% -$4.17M 0.83% 39
2021
Q4 		$23.8M Buy
37,751
+2,811
+8% +$1.73M 0.88% 31
2021
Q3 		$21.1M Buy
34,940
+26,201
+300% +$16.3M 0.8% 35
2021
Q2 		$4.88M Sell
8,739
-314
-3% -$159K 0.19% 116
2021
Q1 		$4.28M Buy
9,053
+87
+1% +$42.4K 0.17% 121
2020
Q4 		$4.33M Buy
8,966
+1,167
+15% +$630K 0.19% 103
2020
Q3 		$4.37M Buy
7,799
+3,487
+81% +$2.11M 0.2% 108
2020
Q2 		$2.69M Buy
+4,312
New +$2.45M 0.14% 140
2020
Q1 		– Sell
-379
Closed -$142K – 380
2019
Q4 		$142K Buy
+379
New +$128K 0.01% 299

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab's REGN Position: Q2 2026 in Review

BI Asset Management Fondsmaeglerselskab increased its Regeneron Pharmaceuticals (REGN) stake by 58% in Q2 2026, buying an estimated $1.29M and bringing the position to 5,132 shares worth $3.2M. The position accounts for 0.03% of the portfolio, ranked #343.

BI Asset Management Fondsmaeglerselskab first reported a position in REGN in Q4 2019 and has held it in 26 quarters since. The position peaked at $23.8M in Q4 2021. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • BI Asset Management Fondsmaeglerselskab held 5,132 shares of Regeneron Pharmaceuticals worth $3.2M as of Q2 2026.
  • BI Asset Management Fondsmaeglerselskab bought 1,893 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.29M.
  • Regeneron Pharmaceuticals made up 0.03% of BI Asset Management Fondsmaeglerselskab's portfolio in Q2 2026, its #343 holding.
  • BI Asset Management Fondsmaeglerselskab first reported a position in Regeneron Pharmaceuticals in Q4 2019 and has held it in 26 quarters since.
  • BI Asset Management Fondsmaeglerselskab's Regeneron Pharmaceuticals position peaked at $23.8M in Q4 2021.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on BI Asset Management Fondsmaeglerselskab's 13F filing for Q2 2026, filed 10 Aug 2026.